|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immunophenotypes were not statistical significantly related to synchronous CRC (<i>P</i> = 0.402, 0.650, 0.127, and 0.068 for CK7, CK20, CDX2, and GCDFP-15, respectively).
|
31772568 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pulmonary metastases of colorectal cancer were positive for CK20 in 83% and CDX2 in 99% of the cases.
|
30389437 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The latter, an mRNA termed KRT20, has been shown to be over-expressed in metastases originating from colorectal cancer (CRC).
|
31121464 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Purpose</b>: Most colorectal cancers (CRCs) show positive immunohistochemical (IHC) staining for CK20 and negative staining for CK7.
|
31258757 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The median time between diagnosis and IBM was 46.7 months (range 0-180).Most CRC metastases are CK7-/CK20+.
|
31087546 |
2019 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 20-positive cells in lymph nodes from pN0 colorectal cancer (CRC) patients were detected previously by us.
|
29467924 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CK20 was expressed in a higher percentage of CRC and nodal metastasis than CK7.
|
29637921 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the utility of dual stain with special AT-rich sequence binding protein 2 (SATB2) or caudal-type homeobox 2 (CDX2) and cytokeratin 20 (CK20) or villin in identifying CRC.
|
29471325 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combining evaluation of SATB2 with CK20 and CDX2 to form a three marker panel further improved the detection of metastatic CRCs in liver biopsy tissues.
|
29396302 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusion Serum CK20 mRNA expression was significantly elevated in colorectal cancer patients which could be a promising serum biomarker for colorectal cancer diagnosis with high specificity.
|
29043299 |
2017 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LEF-1 expression was identified in 35% of colorectal carcinomas that lacked CK20 and CDX2 expression.
|
25394300 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Predictive value of CK20 in evaluating the efficacy of treatment and prognosis after surgery for colorectal cancer.
|
26125781 |
2015 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Statistical analysis revealed that the combination of CK19 and CK20 could be useful in the exclusion of colorectal cancer, as well as the diagnosis and exclusion of gastric cancer.
|
24922677 |
2014 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The CDX2 and CK20 expression statuses were immunohistochemically evaluated in 109 MSI-H CRC tissue samples, and the correlations of these statuses with clinicopathologic, molecular, and survival data were statistically analyzed.
|
24025523 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that CD44(+)/aldehyde dehydrogenase (ALDH)(+) slowly proliferating immature CRC stem cell populations expressed relatively low levels of JARID1B and the differentiation marker, CD20, as well as relatively high levels of the tumor suppressor, p16/INK4A.
|
23354547 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined SMARCB1/INI1 protein expression in 134 cases of colorectal cancer (CRC) and 60 matched normal mucosa by using tissue microarrays and western blot and categorized the results according to mismatch repair status (MMR), CpG island methylator phenotype, biomarkers of tumor differentiation CDX2, CK20, vimentin and p53.
|
24286138 |
2013 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In our study, we performed immunohistochemical staining with CK7 and CK20 in 52 randomly selected cases of CRC and analyzed microsatellite instability status and BRAF mutations to identify those factors that may determine the changing pattern of CK7/CK20 immunophenotype in these tumors.
|
22361037 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the prognostic value of CTC/CSC that express carcinoembryonic antigen (CEA) cytokeratin 19 (CK19), CK20 and/or CD133 (CEA/CK/CD133) mRNA in the tumor drainage blood of CRC patients with Dukes' stage B and C. We examined tumor drainage blood from 197 patients with Dukes' stage B and C CRC.
|
22267181 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim was to explore the utility for staging and prognostic impact of carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), guanylyl cyclase C (GCC), CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenic protein 1) containing domain protein 1 (CDCP1) and mucin 2 (MUC2) mRNA levels in mesenteric lymph nodes of colorectal cancer (CRC) patients.
|
21618511 |
2012 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
(1) Statistically significant high levels of CK20,VEGF, CEA (p = 0.000 each) and CA19-9 (p = 0.002) in CRC patients when compared with controls; (2) Statistically significant increase in the expression of CK20 in advancing CRC stage C (p = 0.001) and with LN metastasis (p = 0.000); (3) Statistically significant increase in the expression of VEGF in advancing CRC stage C (p = 0.002), pathologic grade (p = 0.038), and with LN metastasis (p = 0.004); and (4) statistically positive correlation between CK20 and VEGF expressions, and also between these markers and CEA level.
|
20395351 |
2011 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Indeed, the presence of neuropilin-2 in colorectal carcinoma cell lines was correlated with loss of epithelial markers such as cytokeratin-20 and E-cadherin and with acquisition of mesenchymal molecules such as vimentin.
|
21747928 |
2011 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using RT-PCR we studied HERG, CEA, CK19 and CK20 expression in colorectal carcinomas and non-carcinoma controls.
|
19577877 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The increasing number of positive detections for CEA, CK20 and EGFR transcripts in each blood sample was positively correlated with Astler-Coller disease stage (P < 0.001) and preoperative serum levels of CEA (P = 0.029) in CRC patients.
|
21157973 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Meanwhile, no relationship of CD34, CK19, CK20, and Ki67 with the location of CRC was found (P > 0.05).
|
19340613 |
2010 |
|
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CDX1 and KRT20 mRNA expression were significantly correlated in a panel of 38 colorectal cancer cell lines.
|
19188603 |
2009 |